Published in N Engl J Med on February 07, 1974
Effects of platelet-modifying drugs on arterial thromboembolism in baboons. Aspirin potentiates the antithrombotic actions of dipyridamole and sulfinpyrazone by mechanism(s) independent of platelet cyclooxygenase inhibition. J Clin Invest (1985) 0.95
The Gordon Wilson lecture: function of blood platelets and their role in thrombosis. Trans Am Clin Climatol Assoc (1976) 0.88
Pharmacokinetics of single doses of sulphinpyrazone and its major metabolites in plasma and urine. Br J Clin Pharmacol (1982) 0.78
Dose-dependent inhibition of experimental arterial thrombosis by carbenicillin and ticarcillin. Am J Pathol (1978) 0.77
Potential therapeutic applications of aspirin and other cyclo-oxygenase inhibitors. Br J Clin Pharmacol (1980) 0.77
Intermittent heparin treatment does not induce hypercoagulability in haemodialysed patients. J Clin Pathol (1980) 0.75
Effect of dazoxiben on arterial graft thrombosis in the baboon. Br J Clin Pharmacol (1983) 0.75
The Burlington randomized trial of the nurse practitioner. N Engl J Med (1974) 17.02
Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA (1999) 12.75
A physical map of the human genome. Nature (2001) 12.39
Controversy in counting and attributing events in clinical trials. N Engl J Med (1979) 7.25
Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med (1995) 6.86
Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol (1991) 6.55
Prevention of venous thromboembolism. Chest (2001) 5.59
A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med (1999) 5.14
Management of anticoagulation before and after elective surgery. N Engl J Med (1997) 5.10
Molecular cloning of cDNA encoding human interleukin-2 receptor. Nature (1984) 4.95
Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. Thromb Haemost (2000) 4.81
A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med (1996) 4.70
Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med (1997) 4.47
The Burlington randomized trial of the nurse practitioner: health outcomes of patients. Ann Intern Med (1974) 4.37
Canadian implantable defibrillator study (CIDS) : a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation (2000) 4.12
Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med (2003) 3.94
Organization of the constant-region gene family of the mouse immunoglobulin heavy chain. Cell (1982) 3.72
A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. N Engl J Med (1993) 3.67
The Drosophila ninaE gene encodes an opsin. Cell (1985) 3.65
Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet (1994) 3.51
Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial. Lancet (2000) 3.50
Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset. Science (1984) 3.47
Accuracy of clinical assessment of deep-vein thrombosis. Lancet (1995) 3.45
Limitations of impedance plethysmography in the diagnosis of clinically suspected deep-vein thrombosis. Ann Intern Med (1993) 3.40
Effect of bromhexine on ventilatory capacity in patients with a variety of chest diseases. Lancet (1969) 3.34
Effects of physiologic pacing versus ventricular pacing on the risk of stroke and death due to cardiovascular causes. Canadian Trial of Physiologic Pacing Investigators. N Engl J Med (2000) 3.32
Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med (1992) 3.23
Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med (1982) 3.16
Assessment of outpatient treatment of deep-vein thrombosis with low-molecular-weight heparin. Arch Intern Med (1998) 3.09
The cloned dopa decarboxylase gene is developmentally regulated when reintegrated into the Drosophila genome. Cell (1983) 3.08
Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med (1986) 3.00
Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial. N Engl J Med (1985) 2.99
Complete amino acid sequence of the Mu heavy chain of a human IgM immunoglobulin. Science (1973) 2.97
Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med (1979) 2.91
Significance testing to establish equivalence between treatments, with special reference to data in the form of 2X2 tables. Biometrics (1977) 2.87
Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest (1992) 2.76
A standard heparin nomogram for the management of heparin therapy. Arch Intern Med (1991) 2.69
Prognostic importance of myocardial ischemia detected by ambulatory monitoring early after acute myocardial infarction. N Engl J Med (1996) 2.69
Management of deep vein thrombosis and pulmonary embolism. A statement for healthcare professionals. Council on Thrombosis (in consultation with the Council on Cardiovascular Radiology), American Heart Association. Circulation (1996) 2.69
Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med (1990) 2.63
A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med (1972) 2.60
Antigen-induced apoptotic death of Ly-1 B cells responsible for autoimmune disease in transgenic mice. Nature (1992) 2.52
Use of a clinical model for safe management of patients with suspected pulmonary embolism. Ann Intern Med (1998) 2.49
The North American Vasovagal Pacemaker Study (VPS). A randomized trial of permanent cardiac pacing for the prevention of vasovagal syncope. J Am Coll Cardiol (1999) 2.44
Randomised comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement. Lancet (1988) 2.44
Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review. Ann Intern Med (2001) 2.37
Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol (2000) 2.35
Establishing a therapeutic range for heparin therapy. Ann Intern Med (1993) 2.31
Ultrasonographic screening before hospital discharge for deep venous thrombosis after arthroplasty: the post-arthroplasty screening study. A randomized, controlled trial. Ann Intern Med (1997) 2.28
Ordering of mouse immunoglobulin heavy chain genes by molecular cloning. Nature (1981) 2.28
Comparison of high-dose with low-dose subcutaneous heparin to prevent left ventricular mural thrombosis in patients with acute transmural anterior myocardial infarction. N Engl J Med (1989) 2.28
Managing oral anticoagulant therapy. Chest (2001) 2.25
Platelet-active drugs : the relationships among dose, effectiveness, and side effects. Chest (2001) 2.25
Laparoscopic kidney transplantation: an initial experience. Am J Transplant (2011) 2.24
Cost-effectiveness of pulmonary embolism diagnosis. Arch Intern Med (1996) 2.24
Thrombosis in antithrombin-III-deficient persons. Report of a large kindred and literature review. Ann Intern Med (1992) 2.23
Circular DNA is excised by immunoglobulin class switch recombination. Cell (1990) 2.22
Small subcutaneous doses of heparin in prevention of venous thrombosis. N Engl J Med (1973) 2.17
Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest (1990) 2.14
Real-world variability in dabigatran levels in patients with atrial fibrillation. J Thromb Haemost (2015) 2.07
How should results from completed studies influence ongoing clinical trials? The CAFA Study experience. Ann Intern Med (1991) 2.06
Identification of patients most likely to benefit from implantable cardioverter-defibrillator therapy: the Canadian Implantable Defibrillator Study. Circulation (2000) 2.05
Cost effectiveness of clinical diagnosis, venography, and noninvasive testing in patients with symptomatic deep-vein thrombosis. N Engl J Med (1981) 2.04
Serum pepsinogens as a screening test of extensive chronic gastritis. Gastroenterol Jpn (1987) 2.03
Stroke prevention in nonvalvular atrial fibrillation. Ann Intern Med (1991) 2.01
Guide to anticoagulant therapy: Heparin : a statement for healthcare professionals from the American Heart Association. Circulation (2001) 2.01
Venous thromboembolism prophylaxis: do trial results enable clinicians and patients to evaluate whether the benefits justify the risk? Proceedings of an Ad Hoc Working Group Meeting. J Thromb Haemost (2013) 1.97
Immunoglobulin class switching. Cell (1984) 1.95
Persistent post-splenectomy thrombocytosis and thrombo-embolism: a consequence of continuing anaemia. Br J Haematol (1966) 1.94
Coexistent Hashimoto's thyroiditis with papillary thyroid carcinoma: impact on presentation, management, and outcome. Surgery (1999) 1.94
Quality of life in stage II breast cancer: an instrument for clinical trials. J Clin Oncol (1988) 1.93
Management of suspected deep venous thrombosis in outpatients by using clinical assessment and D-dimer testing. Ann Intern Med (2001) 1.93
Requirement of circadian genes for cocaine sensitization in Drosophila. Science (1999) 1.92
Diagnostic value of ventilation-perfusion lung scanning in patients with suspected pulmonary embolism. Chest (1985) 1.92
Structure of a rearranged gamma 1 chain gene and its implication to immunoglobulin class-switch mechanism. Proc Natl Acad Sci U S A (1981) 1.91
Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. J Bone Joint Surg Br (2009) 1.91
Ectopic G-protein expression in dopamine and serotonin neurons blocks cocaine sensitization in Drosophila melanogaster. Curr Biol (2000) 1.90
A novel and rapid whole-blood assay for D-dimer in patients with clinically suspected deep vein thrombosis. Circulation (1995) 1.90
Interactions of warfarin with drugs and food. Ann Intern Med (1994) 1.88
A transgenic model of autoimmune hemolytic anemia. J Exp Med (1992) 1.87
Mixed chimerism and tolerance without whole body irradiation in a large animal model. J Clin Invest (2000) 1.86
Neonatal coagulation defect due to anticonvulsant drug treatment in pregnancy. Lancet (1970) 1.84
Prevention of deep vein thrombosis after elective hip surgery. A randomized trial comparing low molecular weight heparin with standard unfractionated heparin. Ann Intern Med (1991) 1.81
A human anti-CD40 monoclonal antibody, 4D11, for kidney transplantation in cynomolgus monkeys: induction and maintenance therapy. Am J Transplant (2009) 1.81